Literature DB >> 11751036

Vasopressin mediates the response of the combined dexamethasone/CRH test in hyper-anxious rats: implications for pathogenesis of affective disorders.

Martin E Keck1, Alexandra Wigger, Tobias Welt, Marianne B Müller, Angela Gesing, Johannes M H M Reul, Florian Holsboer, Rainer Landgraf, Inga D Neumann.   

Abstract

To investigate the neuroendocrine alterations linked to inborn emotionality in two Wistar rat lines selectively bred for either high (HAB) or low (LAB) anxiety-related behavior, we administered the combined dexamethasone (DEX)/corticotropin-releasing hormone (CRH) test. DEX (12:00 M. (noon); 30 microg/kg) resulted in a significantly less efficient suppression of the diurnal increase in the circulating corticotropin (ACTH) levels in the male HAB rats than in the male LAB rats. In addition, plasma ACTH and corticosterone responses to subsequent CRH (7:30 P.M.; 50 ng/kg) were significantly higher in male HAB rats. The rise in ACTH after CRH in the DEX-pretreated male HAB rats points toward an enhanced activity and involvement of endogenous vasopressin synthesized in the hypothalamic paraventricular nucleus (PVN) and acting at pituitary corticotrope cells. We tested this hypothesis by in situ hybridization and in vivo microdialysis, and found an increase in both basal synthesis and release of vasopressin within the PVN of the male HAB rats. As expected, pretreatment with a selective vasopressin type 1 receptor antagonist abolished the CRH-stimulated increase in ACTH secretion in the DEX-pretreated male HAB rats. The results indicate that vasopressin-mediated effects are critically involved in the profound disturbance of the hypothalamic-pituitary-adrenocortical system in male HAB rats, thus revealing striking parallels to the neuroendocrine situation in human depression.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11751036     DOI: 10.1016/S0893-133X(01)00351-7

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  23 in total

Review 1.  Endocrine disturbances in depression.

Authors:  M A Tichomirowa; M E Keck; H J Schneider; M Paez-Pereda; U Renner; F Holsboer; G K Stalla
Journal:  J Endocrinol Invest       Date:  2005-01       Impact factor: 4.256

Review 2.  Stress-induced sex differences: adaptations mediated by the glucocorticoid receptor.

Authors:  Chase H Bourke; Constance S Harrell; Gretchen N Neigh
Journal:  Horm Behav       Date:  2012-03-03       Impact factor: 3.587

3.  cDNA microarray analysis of gene expression in anxious PVG and SD rats after cat-freezing test.

Authors:  H Wang; Y Z Zhu; P T-H Wong; J M Farook; A L Teo; L K H Lee; S Moochhala
Journal:  Exp Brain Res       Date:  2003-02-19       Impact factor: 1.972

4.  Gonadal steroid modulation of the limbic-hypothalamic- pituitary-adrenal (LHPA) axis is influenced by social status in female rhesus monkeys.

Authors:  Mark E Wilson; Ariadne Legendre; Karen Pazol; Jeffrey Fisher; Kathy Chikazawa
Journal:  Endocrine       Date:  2005-03       Impact factor: 3.633

5.  Gender-specific association of galanin polymorphisms with HPA-axis dysregulation, symptom severity, and antidepressant treatment response.

Authors:  Paul G Unschuld; Marcus Ising; Darina Roeske; Angelika Erhardt; Michael Specht; Stefan Kloiber; Manfred Uhr; Bertram Müller-Myhsok; Florian Holsboer; Elisabeth B Binder
Journal:  Neuropsychopharmacology       Date:  2010-03-17       Impact factor: 7.853

6.  SSR149415, a non-peptide vasopressin V1b receptor antagonist, has long-lasting antidepressant effects in the olfactory bulbectomy-induced hyperactivity depression model.

Authors:  M E Breuer; M M van Gaalen; W Wernet; S E F Claessens; R S Oosting; B Behl; S M Korte; H Schoemaker; G Gross; B Olivier; L Groenink
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-07-31       Impact factor: 3.000

7.  Aggression and anxiety: social context and neurobiological links.

Authors:  Inga D Neumann; Alexa H Veenema; Daniela I Beiderbeck
Journal:  Front Behav Neurosci       Date:  2010-03-30       Impact factor: 3.558

Review 8.  Translational approaches to anxiety: focus on genetics, fear extinction and brain imaging.

Authors:  Angelika Erhardt; Victor I Spoormaker
Journal:  Curr Psychiatry Rep       Date:  2013-12       Impact factor: 5.285

Review 9.  Innovative approaches for the treatment of depression: targeting the HPA axis.

Authors:  Fiona Thomson; Mark Craighead
Journal:  Neurochem Res       Date:  2007-10-25       Impact factor: 3.996

10.  Tamoxifen is an estrogen antagonist on gonadotropin secretion and responsiveness of the hypothalamic-pituitary- adrenal axis in female monkeys.

Authors:  M E Wilson; D Mook; F Graves; J Felger; I F Bielsky; K Wallen
Journal:  Endocrine       Date:  2003-12       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.